RLX Technology Q2 FY26 earnings call RLX

RLX Technology's Q2 FY26 performance was significantly bolstered by its expanding international footprint, which accounted for approximately 70% of total net revenues. The company is aggressively upgrading its distribution architecture through direct channel investments and strategic partnerships. A key move was the July 2026 controlling investment in a leading B2B and FMCG physical distribution leader in Western Europe, which serves over 30,000 retail endpoints and connects with over 20,000 independent merchants via a proprietary B2B digital commerce platform. This acquisition is expected to unlock significant operational and supply chain synergies and will be fully consolidated starting Q3 2026.

The company acknowledges increasingly detailed and restrictively enforced regulatory oversight across international markets, citing proposed UK regulations on plain packaging, retail display bans, and flavor restrictions. RLX views these shifts as positive long-term developments that push out non-compliant competition and raise entry barriers. The company emphasizes its robust compliance infrastructure, R&D, and supply chain capabilities to meet these standards proactively and engage stakeholders.

RLX is transforming into a multi-category, next-generation smoke-free product platform. Beyond e-vapor, it has commercialized a modern oral nicotine pouch line and is ramping up manufacturing capacity and channel distribution. The company also holds extensive proprietary technology and patent reserves in the heat-not-burn category, with market-ready products awaiting optimal market and regulatory conditions for launch.

To support multi-category expansion and reduce exposure to trade friction, RLX is constructing a state-of-the-art manufacturing hub in Southeast Asia. This facility will cover multiple product categories, improve tariff positions, and streamline logistics, enhancing long-term sales resilience. The company's strategy focuses on building an agile, compliant global platform rather than chasing low-margin volume.

The company maintains a strong balance sheet with RMB 13.9 billion in total capital resources as of June 30, 2026. Its capital allocation strategy prioritizes organic growth and high ROI initiatives (R&D, supply chain localization), selective and accretive M&A, and direct shareholder returns (share repurchases, dividends). M&A targets are benchmarked against comparables, must have clear cash payback, be non-dilutive, and generate EPS accretion.

For Mainland China, the tightening regulatory environment and crackdown on illegal products are seen as positive long-term developments, eliminating illicit trade and redirecting demand to legal brands. However, procedural timelines for government approval have become more conservative, leading to an expectation of broadly flat Mainland China sales for the full year. In the US, RLX monitors regulatory developments but will not commit large-scale capital until regulatory pathways provide long-term credibility, instead focusing on transparent markets in Europe and Asia and scalable reduced-risk categories like nicotine pouches.